SCHEMBL4779334

SCHEMBL4779334

NC(C=O)C(c1ccc(Br)s1)N1Cc2cncnc2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779485 0.83 DPP8 (0.35)
SCHEMBL4779233 0.77 NAMPT (0.34)
SCHEMBL4779060 0.67 CYP1A2 (0.42)
SCHEMBL4910552 0.65 HDAC8 (0.39)
SCHEMBL4779331 0.65 HDAC8 (0.39)
SCHEMBL4778154 0.64 ABL1 (0.34)
SCHEMBL8217044 0.63 NAMPT (0.37)
SCHEMBL20159097 0.58 DPP4 (0.37)
SCHEMBL256350 0.56 CYP3A4 (0.37)
SCHEMBL21495021 0.56 CES2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed